Mr. Brazzale is the Founder, President, and CEO of Gordian Biotechnologies. He was previously co-founder and Vice President of Product and Business Development for Melanovus Oncology, a life science company developing therapeutics for the treatment of metastatic melanoma. A successful exit for Melanovus closed with the sale of the company to Cipher Pharmaceuticals. He began his career at Abbott Laboratories in 1996 as a research scientist in the area of antibiotic drug discovery leading to an eventual clinical phase III candidate, Cethromycin. In 1999 he was recruited by Wyeth to continue his drug development career in the area of woman’s health. He is an inventor on numerous patents and an author of multiple published peer-reviewed journal articles. He left the lab in 2003 to pursue operations, sales, and business development positions in the life sciences with companies including Biotage, Argonaut Technologies, and BIA Separations, where he spent three years as the Vice President of Business Development for North America and special advisor to the Board of Directors.
In 2011 Tony founded Biotech Business Development, Inc., a corporate strategy and finance advisory focused on the global life sciences industry. The company’s mission is to add and create value for therapeutic and technology-based companies by implementing operational improvements and business development strategies.
Tony is a member of a number of scientific and professional societies including the Licensing Executives Society and the American Chemical Society (ACS), where he will began a three-year chair succession in 2012 in the Division of Business Development and Management. He is also an advisor to the Entrepreneurial Resource Center, part of the Entrepreneurial Initiative within the ACS.
Tony earned a Bachelor of Science degree in chemistry from Southern Illinois University in 1996 and also competed as a NCAA Division I swimmer for the Salukis.
Mr. Gordon has more than 25 years of experience in management, finance, and accounting activities. He is also the President of 1st U.S. Capital Markets, Inc., a financial advisory and general management consulting firm. He previously served as a Founder, Board Member, Chief Financial Officer and Corporate Secretary of Neogenix Oncology, Inc., a biotechnology firm developing products for the treatment of pancreatic and colorectal cancer and was also co-founder and Chief Financial Officer at Melanovus Oncology. He served as Vice President of Finance for Concrete Media, a pioneering e-commerce firm; CFO of Bennett X-Ray, a medical device manufacturer; CFO of Cornwall Securities, Inc., a registered broker/dealer; and CFO of US Tele-Com, Inc., the third largest private payphone service in the U.S. He also served as Vice President of Finance for Time-in-Motion, Inc., a custom timepiece manufacturer, and was Director of Business Planning for the Lorus Products Division of the Hattori-Seiko Corporation.
Peter received an AAS degree in Mechanical Engineering from the College of Aeronautics in 1971, a Bachelor of Science degree from Lehman College in 1981, and an MBA from Pace University in 1986.
Dr. Weidmann has 25 years of experience in pharmaceutical research and early development in different disease areas, including cardiovascular, atherosclerosis & metabolic diseases, oncology, immunology & transplantation and infectious diseases. Dr. Weidmann began his career at Sandoz in Basel, Switzerland, and later worked at Novartis Pharmaceuticals in East Hanover, New Jersey, Cambridge, Massachusetts, and Singapore.
In addition to building, coaching and managing multidisciplinary research departments and development teams, Dr. Weidmann has led the discovery and early development of multiple drug candidates. Several of these new chemical entities have progressed to phase I and phase II clinical proof-of-concept trials. Most notably, Dr. Weidmann has successfully initiated and led the buildup of a new R&D initiative in infectious diseases (antibacterials and antivirals) at Novartis. Other responsibilities included business development and licensing, strategic alliances and external collaborations to support this new business initiative.
Dr. Weidmann received a Ph.D. in organic chemistry from the Swiss Federal Institute of Technology in Zurich, followed by postdoctoral training in biochemistry at Brandeis University in Waltham, Massachusetts. He is an author of 15 patents and 24 peer-reviewed papers in scientific journals